SK Biopharmaceuticals said it signed a $62 million licensing agreement to commercialize cenobamate (brand name: Xcopri), an anti-epileptic treatment, in Latin America.

In a public filing on Thursday, the company said it licensed out cenobamate to Eurofarma Laboratorios SA for the commercialization of the treatment in 17 countries in Latin America.

Under the deal, SK Biopharmaceuticals will receive an upfront payment of $15 million. In addition, the company can receive up to $47 million, including milestone payments upon drug approval, sales, and royalties.

The deal will be effective for 10 years after the first market release. After that, if the two agree, they can extend the agreement by one year at a time.

Eurofarma, which will handle cenobamate’s market release and sales, is a Brazil-based multinational pharmaceutical firm. It has expertise in sales and marketing of central nervous system drugs with a sales network across Central and South America.

Eurofarma plans to sell cenobamate in 17 countries in Latin America, including Brazil and Mexico. Latin America is known to have 6 million epilepsy patients, but more than half of them fail to get proper treatment.

In May, SK Biopharmaceuticals partnered with Dexcel Pharma to release cenobamate in Israel.

The company said that the latest deal would help cenobamate reach Latin America, after North America, Europe, and Asia.